Dr. Mikhail Blagosklonny’s Revelation To A Longer Life

Dr. Mikhail Blagosklonny is a professor of Oncology at the Roswell Park Cancer Institute and had studied and conducted research in the area of cancer and its therapies, as well as the subject of aging and increasing the life span. Dr. Blagosklonny is well known for advocating for and spearheading the research for a drug called Rapamycin, which is considered to be a drug used in the fight against cancer, as well as contribution to increasing the human life span. To provide some background information on this drug, Rapamycin, also known as Sirolimus, it was first isolated on Bacterium found on Easter, Island bak in 1972. When discovered, it was first used an as anti-fungal agent. It was then abandoned as an anti-fungal, as further research showed that it possessed immunosuppressive and anti proliferative properties at tremendous levels. Immunosuppressive drugs are given to patients undergoing an organ transplant to prevent the body from rejecting the new organ. In such cases, patients can develop kidney disease, as a lot of these drugs can have an adverse affect on the kidneys over a long period of time.

Rapamycin is different from these drugs, as it shows lower levels of toxins that are harmful to the kidney, thus, making this a safer drug. Dr. Blagosklonny’s ongoing research has shown that Rapamycin aides in enhancing the immunity in the body to help battle the growth of tumors, promoting regression in those tumors at the same time. For these reasons, this drug serves as a great benefit to those patients who have undergone an organ transplant in the prevention of cancer. Although there is no conclusive evidence, it’s believed that this drug can also increase the human life span. In fact, when tested on elderly patients who took the influenza vaccine, initial results showed an immunological rejuvenation.

Dr. Blagosklonny continues his research in hopes of killing cancer cells without killing the good cells that help rejuvenate the mind, along with the body. No only does he want to cure cancer and expand the human life expectancy, but he would like to be able to provide this to patients who may not have the financial ability to participate in certain cancer treatments, because they are too expensive. He feels that cancer treatment should not have to be both excruciating and expensive as cancer treatment is at the present time. Dr. Blagosklonny has made great progress with his research and has been a tremendous influence in his field of expertise. He continues his research and hopes that he will inspire others to join him on his journey and continues where he may leave off, in hopes of creating a cost-effective treatment of a cure to cancer.

Why Dr. Clay Siegall is a key Figure in Cancer Therapy

There has been an increase in the number of firms that are undertaking cancer research. Seattle Genetics has nonetheless remained steadfast in its effort to find cure for cancer. The company’s president and CEO, Clay Siegall has particularly been vocal in raising issues about cancer and the innovations that his company has undertaken in its quest to fight the malevolent illness.

Under his leadership, Seattle Genetics has won hearts with for the impressive advancements that it has made towards ensuring that cancer treatment is no longer seen as a pipe dream. The company itself has rapidly grown and this is attested to by the fact that its stock price has tripled within a span of five years. This growth is owed to Siegall who has a firm dedication towards improving the health of cancer patients. He has been at the helm of Seattle Genetics since 2002.

Dr. Siegall in Brief

Dr. Siegall is a renowned personality in biomedical research with over thirty years of experience under his belt. During his impressive career, he has won admiration for his passion towards groundbreaking cancer research whose aim is to unravel therapies for patients. He actively leads research teams at Seattle Genetics. Since co-founding the biotechnology company in 1998, he has worked tirelessly to ensure that it advances world-class products that will benefit cancer patients for years to come.

Clay earned his doctorate in genetics at the George Washington University. Since making forays into the field of cancer research, he has carved a hugely successful career for himself. He has also won numerous personal and professional accomplishments for his work. His research career begun at Bristol-Myers Squibb Pharmaceutical Research Institute where he was a senior research investigator. His diligence, enthusiasm, and dedication saw him become chief scientist at the firm. Later on, he moved to the National Cancer Institute where he was a biotechnology fellow and staff fellow.

Dr. Siegall owes his success to the supporting cast that he has had around him for much of his career. He concedes that scientific research is about teamwork. He mainly focuses on research that banks on cutting-edge developments. The passion that he has towards his work has seen him mold Seattle Genetics into the ultimate industry leader in cancer research.